Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Recent scientific discoveries have identified several new genetic markers that significantly advance our understanding of Alzheimer’s disease risk and progression. In October 2024, researchers at Indiana University School of Medicine identified a critical genetic variant called rs2113389 on chromosome 2p22.2 that shows a strong association with tau burden—a hallmark protein that damages the brain in Alzheimer’s patients. This discovery, combined with findings about other genetic variants and their roles in Alzheimer’s development, represents a major breakthrough in identifying who may be at higher risk for cognitive decline and opening new pathways for targeted treatments.
These genetic discoveries matter because they shift how researchers and physicians think about Alzheimer’s disease. Rather than viewing it as a single condition with one cause, scientists now recognize it as a complex disease influenced by multiple genes that affect different biological pathways. Understanding these genetic markers allows doctors to identify at-risk individuals years or decades before symptoms appear, potentially enabling early interventions that could slow cognitive decline or prevent disease onset altogether.
Table of Contents
- What Are the New Genetic Markers Identified for Alzheimer’s Risk?
- How Do These Genetic Markers Influence Alzheimer’s Development?
- The Significance of Tau Biomarkers in Early Detection
- New Drug Development Targets Emerging from Genetic Research
- Current Limitations and Challenges in Genetic Marker Research
- The Role of Tau, Amyloid, and Newly Identified Proteins
- Looking Forward—The Path to Precision Alzheimer’s Medicine
- Conclusion
What Are the New Genetic Markers Identified for Alzheimer’s Risk?
The emerging picture of Alzheimer’s genetics involves several key variants working in concert. The rs2113389 variant discovered by Indiana researchers lies between the CYP1B1 and RMDN2 genes and has shown strong associations with tau accumulation across multiple brain regions—a finding that could help researchers develop treatments specifically targeting tau-related damage. Separately, scientists have identified variations in the PLCG2 gene that dramatically influence disease susceptibility. The M28L variant increases the risk of developing Alzheimer’s, while the intriguing P522R variant actually reduces risk, suggesting that some genetic changes can be protective against cognitive decline.
These discoveries complement decades of research on the APOE gene, which has long been known to influence Alzheimer’s risk. The APOE ε4 variant significantly increases risk, while APOE ε2 offers protection. Recent Stanford research published in January 2024 in the journal Neuron has explored whether increasing APOE ε2 protein levels in people carrying the high-risk APOE ε4 variant could provide therapeutic benefits—essentially trying to boost the protective variant’s effects even in those genetically predisposed to disease. This represents a fundamental shift in how researchers approach genetic risk: instead of accepting genetic destiny, scientists are exploring ways to counteract harmful variants through targeted interventions.
How Do These Genetic Markers Influence Alzheimer’s Development?
The newly identified genetic markers work through distinct biological mechanisms in the brain. The tau-associated rs2113389 variant appears to influence how tau proteins misfold and aggregate, essentially determining how efficiently the disease process begins in the brain. Tau tangles kill neurons by disrupting normal cellular function, so understanding which genetic factors accelerate tau buildup could help researchers develop drugs that slow this specific pathway. This is particularly significant because tau pathology often begins in brain regions associated with memory—the entorhinal cortex and hippocampus—before spreading to wider areas.
The PLCG2 variants operate through a different mechanism, working within microglial cells that serve as the brain’s immune system. When these immune cells function improperly, they may fail to clear away harmful protein accumulations or may themselves cause inflammation that damages neighboring neurons. Research indicates that the protective P522R variant enhances microglia’s ability to respond to threats, while the harmful M28L variant dampens this protective response. A critical limitation in current research is that most genetic findings come from studies in populations of European ancestry, meaning that genetic risk factors may differ in other populations—a gap that researchers are actively working to address but one that limits how universally applicable these findings are for all demographic groups.
The Significance of Tau Biomarkers in Early Detection
The discovery of genetic markers associated with tau burden has major implications for early detection and prevention strategies. Tau tangles and amyloid-beta plaques have long been recognized as the brain pathology of Alzheimer’s disease, but researchers have struggled to identify who will develop problematic accumulations before symptoms appear. The rs2113389 variant provides a genetic predictor of tau burden, meaning individuals carrying this variant could theoretically be identified through genetic testing and enrolled in preventive treatment trials before cognitive symptoms emerge.
In practical terms, consider a 50-year-old person with a family history of Alzheimer’s who carries the rs2113389 variant. Genetic testing could identify them as someone likely to develop tau pathology, and then advanced brain imaging (PET scans) could confirm whether accumulation is actually occurring. This combination of genetic and imaging information could allow doctors to intervene with treatments designed to slow tau aggregation—if such treatments prove effective in ongoing clinical trials. The challenge, however, is that having a genetic risk factor doesn’t guarantee disease development; many people with Alzheimer’s risk genes never develop cognitive decline, suggesting that other factors—lifestyle, other genetic variants, environmental exposures—play crucial moderating roles.
New Drug Development Targets Emerging from Genetic Research
The discoveries about microglial proteins and tau pathways have accelerated drug development efforts. In May 2025, MIT researchers announced potential new targets for Alzheimer’s drug development based on understanding how genes influence protein aggregation and brain inflammation. These targeted approaches differ fundamentally from older drugs like aducanumab, which broadly attempted to clear amyloid-beta with limited success. Instead, researchers are developing treatments tailored to specific genetic pathways—essentially creating precision medicine approaches to Alzheimer’s.
Gene therapy represents one promising direction emerging from this research. NIH-funded studies have shown that APOE ε2 gene therapy in animal models reduced amyloid deposition and improved markers of neuroinflammation, suggesting that boosting the protective APOE ε2 variant could counteract the harmful effects of APOE ε4. However, a significant tradeoff exists: gene therapy approaches, while potentially powerful, are still in early research stages and face challenges including safely delivering genetic material to the brain and managing potential side effects. Traditional small-molecule drugs that modulate the proteins encoded by risk variants offer a different approach—potentially safer but perhaps less potent—and represent a more immediate path to patient treatment.
Current Limitations and Challenges in Genetic Marker Research
While the newly identified genetic markers represent genuine advances, important limitations constrain their current clinical utility. First, having a genetic marker associated with Alzheimer’s risk does not mean that person will definitely develop the disease. The rs2113389 variant increases tau burden risk, but many people with this variant and even elevated tau accumulation never develop symptoms. This creates a clinical dilemma: if doctors identify someone with genetic risk, what preventive treatment should they recommend, and are the side effects of such treatment justified for people who may never experience cognitive decline? Second, most genetic discovery research has focused on people of European descent, creating a significant knowledge gap for other populations.
The prevalence of specific genetic variants differs across ancestry groups, and the effects of variants may also vary by population. A person of African descent carrying the same rs2113389 variant may have different disease risks compared to a person of European ancestry, but current research data cannot reliably answer this question. Until genetic research becomes more inclusive and diverse, recommendations based on genetic markers may inadvertently be less accurate or applicable for historically underrepresented populations. Additionally, genetic markers account for only a portion of Alzheimer’s risk; environmental factors like education level, cardiovascular health, cognitive engagement, and sleep quality remain major modifiable risk factors that may matter as much or more than genetics for many individuals.
The Role of Tau, Amyloid, and Newly Identified Proteins
Beyond established pathology, recent research has identified additional proteins that accelerate Alzheimer’s pathology. In August 2024, scientists discovered that midkine and pleiotrophin—two less-well-known proteins—actively accelerated amyloid aggregation in both laboratory studies and mouse model testing. These proteins essentially act as molecular scaffolding that helps amyloid-beta misfold into toxic forms, suggesting they could be new drug targets for slowing disease progression.
This discovery expands the therapeutic landscape significantly. Rather than attempting to clear amyloid after it accumulates, drugs that block midkine or pleiotrophin could prevent the initial formation of toxic amyloid aggregates—a fundamentally preventive approach. However, this also illustrates a challenge in Alzheimer’s research: the disease involves numerous biological pathways, and no single intervention likely addresses all of them effectively for all patients.
Looking Forward—The Path to Precision Alzheimer’s Medicine
The convergence of genetic discoveries, biomarker research, and new therapeutic targets suggests that Alzheimer’s treatment is moving toward a precision medicine model. The National Institute on Aging’s 2025 Dementia Research Progress Report documents the rapid advancement in this field, with multiple drug candidates in clinical trials targeting specific genetic pathways and protein cascades.
Rather than a one-size-fits-all approach, future treatment may involve identifying which specific genetic and biological factors are driving cognitive decline in an individual patient, then prescribing treatments tailored to address those particular pathways. This shift holds genuine promise, but it also requires sustained research investment and the expansion of genetic diversity in research cohorts. The discoveries made so far represent a critical step forward, yet they also highlight how much remains unknown about the genetic architecture of Alzheimer’s disease across human populations.
Conclusion
Recent discoveries of new genetic markers—particularly the rs2113389 variant associated with tau burden, PLCG2 variants affecting immune function, and the implications of APOE gene therapy—represent a watershed moment in Alzheimer’s research. These findings move the field from viewing Alzheimer’s as a single disease to understanding it as a genetically heterogeneous condition where different variants contribute to risk through distinct biological mechanisms.
As research continues to identify additional genetic factors and develop treatments targeting specific pathways, the possibility of intervening before cognitive decline begins becomes increasingly realistic. For individuals concerned about Alzheimer’s risk, particularly those with family history or advanced age, these discoveries suggest that genetic testing and biomarker evaluation may soon become routine parts of cognitive health assessment. While genetic markers alone cannot predict who will develop dementia, they provide valuable information that, combined with brain imaging, cognitive testing, and lifestyle assessment, can help guide decisions about preventive interventions and lifestyle modifications aimed at preserving brain health.
